401
Participants
Start Date
April 24, 2018
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
MEDI5752
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
Pemetrexed
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
Carboplatin
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
Pembrolizumab
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
Paclitaxel or Nab-Paclitaxel
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
Research Site, Roma
Research Site, Randwick
Research Site, Melbourne
Research Site, Melbourne
Research Site, Taipei
Research Site, New York
Research Site, Gyeonggi-do
Research Site, A Coruña
Research Site, Incheon
Research Site, Fairfax
Research Site, Chapel Hill
Research Site, Majadahonda
Research Site, Cheongju-si
Research Site, Málaga
Research Site, Pamplona
Research Site, Bordeaux
Research Site, Nashville
Research Site, Chattanooga
Research Site, Taichung
Research Site, Valencia
Research Site, Meldola
Research Site, Ravenna
Research Site, Detroit
Research Site, Lyon
Research Site, Tainan City
Research Site, Napoli
Research Site, Villejuif
Research Site, Providence
Research Site, Amsterdam
Research Site, Lisbon
Research Site, Porto
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Lead Sponsor
MedImmune LLC
INDUSTRY